Gadofosveset
![]() | |
| Systematic (IUPAC) name | |
|---|---|
|
Trisodium 2-{[(2R)-2-[bis(2-oxido-2-oxoethyl)amino]-3-[(4,4-diphenylcyclohexyl)oxy-oxidophosphoryl]oxypropyl]-[2-[bis(2-oxido-2-oxoethyl)amino]ethyl]amino}acetate | |
| Clinical data | |
| Trade names | Vasovist, Ablavar |
| Pregnancy category |
|
| Routes of administration | Intravenous |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | 193901-90-5 |
| ATC code | V08CA11 (WHO) |
| PubChem | CID 158440 |
| DrugBank | DB06705 |
| ChemSpider | 139381 |
| KEGG |
D08005 |
| Chemical data | |
| Formula | C33H40GdN3Na3O15P |
| Molar mass | 975.88 g/mol |
| |
| |
Gadofosveset (trade names Vasovist, Ablavar) is a gadolinium-based MRI contrast agent. It is used in form of the trisodium salt.[1][2] It acts as a blood pool agent by binding to human serum albumin.
References
| ||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Tuesday, April 05, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
